173 related articles for article (PubMed ID: 11493246)
1. A pharmacokinetic model for factor VIII dosing during active haemorrhage in patients with haemophilia A.
Ho AM; Dion P; Karmakar MK; Cheng G; Derrick JL; Chung DC; Tay BA
Anaesthesia; 2001 Aug; 56(8):785-90. PubMed ID: 11493246
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of factor VIII in patients with classic haemophilia.
Messori A; Longo G; Matucci M; Morfini M; Ferrini PL
Clin Pharmacokinet; 1987 Dec; 13(6):365-80. PubMed ID: 3125001
[TBL] [Abstract][Full Text] [Related]
3. Continuous infusion of factor VIII concentrates in obese patients with severe haemophilia A: is weight-based dose-adjustment required?
Boban A; Henrard S; Lambert C; Hermans C
Haemophilia; 2016 Jan; 22(1):e62-4. PubMed ID: 26560746
[No Abstract] [Full Text] [Related]
4. Experience of tailoring prophylaxis using factor VIII pharmacokinetic parameters estimated with myPKFiT
Álvarez-Román MT; Fernandez-Bello I; de la Corte-Rodríguez H; Hernández-Moreno AL; Martín-Salces M; Butta-Coll N; Rivas-Pollmar MI; Rivas-Muñoz S; Jiménez-Yuste V
Haemophilia; 2017 Jan; 23(1):e50-e54. PubMed ID: 28074560
[No Abstract] [Full Text] [Related]
5. Unexpected pharmacokinetics of recombinant porcine factor VIII in a patient with acquired factor VIII deficiency and spontaneous epidural haematoma.
Shatzel JJ; Azar S; Scherber R; Gay N; Deloughery TG; VanSandt A; Kruse-Jarres R; Recht M; Taylor JA
Haemophilia; 2017 Sep; 23(5):e453-e456. PubMed ID: 28664642
[No Abstract] [Full Text] [Related]
6. Massive retroperitoneal haemorrhage in a neonate with severe haemophilia A.
Grizelj R; Vuković J; Bilić E; Stern-Padovan R
Haemophilia; 2011 May; 17(3):547-8. PubMed ID: 21070491
[No Abstract] [Full Text] [Related]
7. Improvement in clinical outcomes and replacement factor VIII use in patients with haemophilia A after factor VIII pharmacokinetic-guided prophylaxis based on Bayesian models with myPKFiT
Mingot-Castellano ME; Parra R; Núñez R; Martorell M
Haemophilia; 2018 Sep; 24(5):e338-e343. PubMed ID: 30028549
[TBL] [Abstract][Full Text] [Related]
8. Choice of factor VIII/IX regimen in adolescents and young adults with severe or moderately severe haemophilia. A French national observational study (ORTHem 15-25).
Meunier S; d'oiron R; Chambost H; Dolimier E; Guillet B;
Thromb Res; 2017 Mar; 151():17-22. PubMed ID: 28088606
[TBL] [Abstract][Full Text] [Related]
9. The "OPTI-CLOT" trial. A randomised controlled trial on periOperative PharmacokineTIc-guided dosing of CLOTting factor concentrate in haemophilia A.
Hazendonk HC; van Moort I; Fijnvandraat K; Kruip MJ; Laros-van Gorkom BA; van der Meer FJ; Meijer K; Peters M; Schutgens RE; Zwaan CM; Driessens MH; Polinder S; Leebeek FW; Mathôt RA; Cnossen MH
Thromb Haemost; 2015 Aug; 114(3):639-44. PubMed ID: 26062822
[TBL] [Abstract][Full Text] [Related]
10. Haemostatic response to factor VIII administration in patients with haemophilia A measured by thrombin generation and correlation with factor concentrate use.
Hugenholtz GC; Luddington R; Baglin T
Haemophilia; 2016 Jan; 22(1):e42-5. PubMed ID: 26388112
[No Abstract] [Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice.
Elm T; Karpf DM; Øvlisen K; Pelzer H; Ezban M; Kjalke M; Tranholm M
Haemophilia; 2012 Jan; 18(1):139-45. PubMed ID: 21771205
[TBL] [Abstract][Full Text] [Related]
12. A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients.
Hazendonk H; Fijnvandraat K; Lock J; Driessens M; van der Meer F; Meijer K; Kruip M; Gorkom BL; Peters M; de Wildt S; Leebeek F; Cnossen M; Mathôt R;
Haematologica; 2016 Oct; 101(10):1159-1169. PubMed ID: 27390359
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of recombinant and plasma-derived factor VIII products in paediatric patients with severe haemophilia A.
Steele MR; Nagel K; Chan AK
Haemophilia; 2014 Jan; 20(1):e100-1. PubMed ID: 24251412
[No Abstract] [Full Text] [Related]
14. Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A-LONG study subjects with severe haemophilia A.
Shapiro AD; Mahlangu JN; Perry D; Pasi J; Quon DV; Chowdary P; Tsao E; Li S; Innes A; Pierce GF; Allen GA
Haemophilia; 2017 May; 23(3):392-399. PubMed ID: 28220631
[TBL] [Abstract][Full Text] [Related]
15. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
[TBL] [Abstract][Full Text] [Related]
16. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A.
Martinowitz U; Schulman S; Gitel S; Horozowski H; Heim M; Varon D
Br J Haematol; 1992 Dec; 82(4):729-34. PubMed ID: 1482660
[TBL] [Abstract][Full Text] [Related]
17. Continuous infusion of factor VIII for surgery and major bleeding.
Hay CR; Doughty HI; Savidge GF
Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S15-9. PubMed ID: 8735792
[TBL] [Abstract][Full Text] [Related]
18. Extended half-life factor VIII for immune tolerance induction in haemophilia.
Malec LM; Journeycake J; Ragni MV
Haemophilia; 2016 Nov; 22(6):e552-e554. PubMed ID: 27640873
[No Abstract] [Full Text] [Related]
19. Cerebral haemorrhage in haemophilia.
Bennett M; Sills JA
Postgrad Med J; 1978 Feb; 54(628):115-8. PubMed ID: 634872
[TBL] [Abstract][Full Text] [Related]
20. Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq
Dargaud Y; Negrier C; Rusen L; Windyga J; Georgiev P; Bichler J; Solomon C; Knaub S; Lissitchkov T; Klamroth R
Haemophilia; 2018 Jul; 24(4):619-627. PubMed ID: 29855112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
